Justin Cope

Followers

Following

174

Public Views

Artificial Intelligence, Cognitive Science, Data Science/Machine Learning/Statistical Learning, Causal Inference, Computational Biology/Bioinformatics/Genomics, Computational Linguistics/Natural Language Processing, Corpus Linguistics, Syntax/Semantics

less

Galen Strawson

The University of Texas at Austin

Steven Pinker

Harvard University

Na'ama Pat-El

The University of Texas at Austin

Michael Spivey

University of California, Merced

Ekaterina Kislova

National Research University “Higher School of Economics” (HSE), Moscow, Russia

Bert Vaux

University of Cambridge

Mark W. Post

The University of Sydney

Tamás Tölgyesi

University of Vienna

Shaun Gallagher

University of Memphis

Louis de Saussure

University of Neuchâtel

InterestsView All (15)

Uploads

Papers by Justin Cope

Validation of L-Type Calcium Channel Blocker Amlodipine as a Novel ADHD Treatment through Cross-Species Analysis, Drug-Target Mendelian Randomization, and clinical evidence from medical records

medRxiv (Cold Spring Harbor Laboratory), May 31, 2024

Exploring disease-causing traits for drug repurposing in critically ill COVID-19 patients: A causal inference approach

iScience

Critically ill COVID-19 status associated trait genetics reveals CDK6 inhibitors as potential treatment

Research Square (Research Square), Jun 4, 2021

Despite the recent development of vaccines and monoclonal antibodies preventing SARS-CoV-2 infect... more Despite the recent development of vaccines and monoclonal antibodies preventing SARS-CoV-2 infection, treating critically ill COVID-19 patients still remains a top goal. In principle, drug repurposing-the use of an already existing drug for a new indication-could provide a shortcut to a treatment. However, drug repurposing is often very speculative due to lack of clinical evidence. We report here on a methodology to find and test drug target candidates for drug repurposing. Using UK Biobank data, we matched critically ill COVID-19 cases with healthy controls and screened for significant differences in 33 blood cell types, 30 blood biochemistries, and body mass index. Significant differences in traits that have been associated with critically ill COVID-19 status in prior literature, such as alanine aminotransferase, body mass index, C-reactive protein, and neutrophil cell count, were further investigated. In-depth statistical analysis of COVID-19 associated traits and their genetics using regression modeling and propensity score stratification identified cyclin-dependent kinase 6 (CDK6) as a more promising drug target for the selective treatment of critically ill COVID-19 patients than the previously reported interleukin 6. Four existing CDK6 inhibitors-abemaciclib, ribociclib, trilaciclib, and palbociclib-have been approved for the treatment of breast cancer. Clinical evidence for CDK6 inhibitors in treating critically ill COVID-19 patients has been reported. Further clinical investigations are ongoing.

Justin Cope

Uploads

Papers by Justin Cope

Log In